Feed RDY
RD

Dr. Reddy's Laboratories RDY NYSE · Healthcare · India

$14.89 +0.40% +$0.06

Summary

49 / 100 · Bulios Score

What speaks for it

  • Revenue grew by 13% a year over the last 3 years.
  • It could repay all its net debt from 1.1 years of operating profit.

What to watch

  • It cut its dividend by 81% last year.
  • The share price is above the Bulios Fair Price.
  • It earns only 4.8 INR a year on every 100 INR of invested capital.

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Score in detail

Price

Is it expensive?

Looks expensive
Bulios Fair Price
Overvalued Price today $14.89

By our assumptions the business is worth less than its shares cost today.

P/E today 41.2 94% higher
5-year average P/E 21.2
P/E today 41.2
Drug Manufacturers - Specialty & Generic industry median

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Today you pay 41.2 INR for 1 INR of yearly profit. Over the last five years it was 21.2 INR on average.

Valuation in detail

Is it growing?

Slowly

Revenue (INR)

Diluted EPS (INR)

  • Analyst estimate

Revenue grew by 168% a year over 5 years. Over the last 3 years it grew by 13% a year. For the next fiscal year analysts expect revenue to grow by 0.7%. Earnings per share fell by 0.2% a year over the last 3 years.

Growth in detail

Does it make money?

Reasonably

Where 100 INR of revenue goes

Net profit, industry median (Drug Manufacturers - Specialty & Generic) 9.9 INR

Out of every 100 INR of revenue, 8.5 INR is left as net profit.

Profitability in detail

Is it financially healthy?

Yes

Repaying all its debt would take 6.0 years of free cash flow. It holds more cash than debt.

Financial health in detail

Does it pay a dividend?

Small, stretched
Yield
0.56%
Paid out of profit
23%

You receive $0.08 per share a year. The payout takes a large part of its profit or free cash flow.

Dividends in detail

What do analysts expect?

Mildly positive

Today's price within the analysts' price targets

The average target of $14.8 is 0.6% below today's price. 50% of the analysts recommend buying.

Analysts in detail

What does it earn on?

Fiscal year 2026

By product

The company reports no revenue by product.

By region

Others Countries Country brings in 35% of revenue.

Segments in detail

We use essential cookies to run the website and optional analytics cookies to measure usage.

Privacy policy